Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Melanoma, Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)WithdrawnNCT01340729
What this trial is testing

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT02482532
What this trial is testing

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

Who this might be right for
Melanoma
Gary Doolittle 7
Testing effectiveness (Phase 2)Study completedNCT01530698
What this trial is testing

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

Who this might be right for
Melanoma
Radboud University Medical Center 28
Early research (Phase 1)Study completedNCT00580320
What this trial is testing

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Who this might be right for
MelanomaSoft Tissue SarcomaParathyroid Carcinoma+2 more
Virginia Commonwealth University 17
Not applicableStudy completedNCT02724488
What this trial is testing

Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies

Who this might be right for
Head and Neck CancerMelanoma
University Health Network, Toronto 14
Testing effectiveness (Phase 2)Looking for participantsNCT05379985
What this trial is testing

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Revolution Medicines, Inc. 754
Not applicableStudy completedNCT06495008
What this trial is testing

Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy

Who this might be right for
MelanomaNon-small Cell Lung Cancer (NSCLC)Urogenital Cancers
University Medical Center Groningen 101
Large-scale testing (Phase 3)Study completedNCT03131713
What this trial is testing

Preoperative Acetaminophen and Carbohydrate Loading

Who this might be right for
Non-melanoma Skin Cancer
Tufts Medical Center 101
Not applicableStudy completedNCT01905891
What this trial is testing

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

Who this might be right for
Actinic KeratosisSquamous Cell Carcinoma
Northwestern University 7
Testing effectiveness (Phase 2)Study completedNCT00121225
What this trial is testing

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Who this might be right for
Ciliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaIris Melanoma+4 more
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Looking for participantsNCT07287917
What this trial is testing

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Who this might be right for
Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc. 92
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07651618
What this trial is testing

A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma (Skin Cancer)Melanoma Metastatic
East Metropolitan Health Service, Australia 10
Early research (Phase 1)Looking for participantsNCT03819296
What this trial is testing

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Who this might be right for
Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8+41 more
M.D. Anderson Cancer Center 800
Early research (Phase 1)Looking for participantsNCT05107674
What this trial is testing

NX-1607 in Adults With Advanced Malignancies

Who this might be right for
Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more
Nurix Therapeutics, Inc. 345
Testing effectiveness (Phase 2)Ended earlyNCT01138410
What this trial is testing

Study of a DNA Immunotherapy to Treat Melanoma

Who this might be right for
Malignant Melanoma
Scancell Ltd 35
Early research (Phase 1)Looking for participantsNCT05492682
What this trial is testing

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Who this might be right for
Melanoma (Skin)Triple-Negative Breast CancerNon-Small Cell Lung Cancer+5 more
Valo Therapeutics Oy 15
Testing effectiveness (Phase 2)Ended earlyNCT01453361
What this trial is testing

Phase II FANG™ in Advanced Melanoma

Who this might be right for
Advanced Melanoma
Gradalis, Inc. 18
Testing effectiveness (Phase 2)Study completedNCT00019890
What this trial is testing

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Who this might be right for
Stage IV MelanomaStage III MelanomaRecurrent Melanoma
National Cancer Institute (NCI)
Not applicableStudy completedNCT03948724
What this trial is testing

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Who this might be right for
Therapeutic Patient EducationImmune Checkpoint InhibitorsMelanoma+4 more
Institut Cancerologie de l'Ouest 412
Next Page